ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN KOMBINASI SULFONILUREA-AKARBOSE DENGAN SULFONILUREA-METFORMIN PADA TERAPI DIABETES MELITUS TIPE 2 DI RSPAD GATOT SOEBROTO

• Main Author: Nuur Nazhira, (Author)
• Format: Book
• Published: 2023-12-15.
• Subjects: Thesis; NonPeerReviewed
• Online Access: Link Metadata
• Notes: http://repository.upnvj.ac.id/27649/1/ABSTRAK.pdf; http://repository.upnvj.ac.id/27649/2/AWAL.pdf; http://repository.upnvj.ac.id/27649/3/BAB%201.pdf; http://repository.upnvj.ac.id/27649/4/BAB%202.pdf; http://repository.upnvj.ac.id/27649/5/BAB%203.pdf; http://repository.upnvj.ac.id/27649/6/BAB%204.pdf; http://repository.upnvj.ac.id/27649/7/BAB%205.pdf; http://repository.upnvj.ac.id/27649/8/DAFTAR%20PUSTAKA.pdf; http://repository.upnvj.ac.id/27649/9/RIWAYAT%20HIDUP.pdf; http://repository.upnvj.ac.id/27649/10/LAMPIRAN.pdf; http://repository.upnvj.ac.id/27649/12/HASIL%20PLAGIARISME.pdf; http://repository.upnvj.ac.id/27649/11/ARTIKEL%20KI.pdf
• Keywords: R Medicine (General); RA0421 Public health. Hygiene. Preventive Medicine; RM Therapeutics. Pharmacology

Diabetes mellitus is a disease caused by metabolic problems which is recognized by an increase in blood glucose levels due to impaired insulin secretion, insulin action, or both. Diabetes is a serious problem in the world, where the incidence increase every year until by 2045 it is estimated that it will reach 783 million people. There are several indications of therapeutic options in the treatment of type 2 diabetes mellitus. A combination of two antidiabetic drugs with different mechanisms can be given if the HbA1C value is more than 7.5% or if monotherapy within 3 months results in an HbA1C value of more than 7%. The antidiabetic drugs sulfonylurea, acarbose, and metformin are types of drugs commonly used in Indonesia. The variety of antidiabetic drug therapies can cause differences in the cost and effectiveness of therapy, so the aim of this study is to analyze the cost-effectiveness between combination therapy of sulfonylurea-acarbose and sulfonylurea-metformin. This research was carried out using a cost-effectiveness analysis method with a cross-sectional research design, data collection was carried out by recording medical record data and patient costs during the period January-December 2022. The results showed that there were differences in achieving the HbA1C target in patients using sulfonylurea-acarbose and sulfonylurea therapy. -metformin but statistically this difference was not significant. The average direct medical costs show that the sulfonylurea-metformin combination is lower than sulfonylurea-acarbose and there is a significant difference in the average direct medical costs of the two combinations. The results of the cost-effectiveness calculation of the sulfonylurea-metformin combination are more cost effective with an ACER value of IDR 35,851.83 compared to sulfonylurea-acarbose.